Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.
With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.
AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.
The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.
When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company?
The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
Sales of the French firm’s new products missed consensus forecasts but CEO David Loew is confident that those drugs and the therapies that are close to the market will be commercial successes.
The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.
The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.
BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.
The Swiss major looks to have bagged a bargain in buying MorphoSys and its potential game-changer myelofibrosis candidate pelabresib.
Data may prove too little too late for the antibody drug conjugate, as GSK takes a cautious stance over future commercial viability.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.